Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DeLLphi-305: tarlatamab plus durvalumab versus durvalumab alone after first-line platinum-etoposide-durvalumab in extensive-stage small cell lung cancer
MOH_2024-08-12_013578Phase 3Active, not recruiting
- Sponsor
- Amgen
- Start
- Aug 2024
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in small cell lung cancer (SCLC) comparing Tarlatamab + durvalumab with Durvalumab alone (2 arms). Primary endpoint: Overall survival. Started Aug 2024; status: active, not recruiting.
02
Drugs
tarlatamabdurvalumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on MOH_2024-08-12_013578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-08-12_013578.